Chronic Idiopathic Thrombocytopenic Purpura
2
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Kissei PharmaceuticalJapan - Matsumoto City
1 programfostamatinibN/ASmall Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
ViiV HealthcareSB-497115-GR 12.5mg
BiocorpGammaplex, intravenous immunoglobulin
Kissei Pharmaceuticalfostamatinib
Clinical Trials (3)
Total enrollment: 207 patients across 3 trials
Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Start: Sep 2007Est. completion: Dec 200823 patients
Phase 3Completed
A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Start: Sep 2007Est. completion: Aug 201135 patients
Phase 3Completed
Special Drug Use-results Survey for Long-term Use (Fostamatinib)
Start: May 2023Est. completion: Sep 2028149 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 207 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.